Pfizer Posts Phase 3 Litfulo Vitiligo Data, Setting Up FDA And EMA Filings

Pfizer said detailed Phase 3 data presented Friday at the European Academy of Dermatology and Venereology annual meeting support regulatory submissions for Litfulo in nonsegmental vitiligo, a chronic autoimmune skin disorder with limited treatment options. The company said it plans to submit the results to the FDA and the European Medicines Agency.

That matters because Litfulo, or ritlecitinib, is already marketed as a once-daily oral treatment for alopecia areata after its first FDA approval in 2023. A vitiligo expansion would move Pfizer into a category where treatment options remain sparse but competition is building, with systemic drugs now trying to challenge a market led in the U.S. by a topical therapy.

The data

Pfizer ran two global Phase 3 studies evaluating a high dose and a low dose of Litfulo in nonsegmental vitiligo, enrolling a total of 2,174 patients. In the U.S., the two main goals were the proportion of patients achieving at least 75% improvement on a facial repigmentation scale and the proportion achieving 50% improvement across the entire body, both measured at week 52. Outside the U.S., the 75% facial measure was the primary endpoint and the 50% body measure was a key secondary endpoint.

At week 52, 21.8% of patients on the high dose achieved the facial measure, compared with 12.4% on the low dose and about 2.4% on placebo. On total-body repigmentation, 13% of the high-dose cohort met the trial goal versus about 2.4% of placebo patients. In the low-dose group, 8.9% reached that mark compared with 1.9% of placebo recipients.

Pfizer said improvement began appearing at week 24 and continued through week 52. In a prepared statement included in the company’s announcement, Dr. Iltefat Hamzavi of Henry Ford Health and Hamzavi Dermatology Specialists said the research showed significant gains in facial and total-body repigmentation as well as greater disease stabilization than placebo.

The most common treatment-emergent adverse events were respiratory tract infections, higher blood levels of creatine phosphokinase, nasopharyngitis, and headache. Pfizer said event rates were low in both studies, no new safety signals were observed, and Litfulo’s safety remained consistent with the drug’s profile in alopecia areata.

The commercial picture

Vitiligo affects an estimated 1% to 1.5% of the global population, or about 70 million people, according to the Global Vitiligo Foundation cited in the report. Nonsegmental vitiligo, also called generalized vitiligo, is the more common form and typically appears on both sides of the body, with visible effects often affecting the face, neck, and hands.

The commercial opening is real, but it is no longer empty. Litfulo would be entering against Opzelura, Incyte’s topical ruxolitinib cream, which the source describes as the only FDA-approved vitiligo drug. Incyte reported $678.5 million in Opzelura revenue for 2025, up 33.4% from the prior year, though that revenue also includes atopic dermatitis use.

The strategic distinction for Pfizer is route and mechanism positioning. Litfulo is an oral small molecule that blocks JAK3 and TEC proteins, giving Pfizer a systemic treatment angle in a disease where visible skin involvement can be extensive. If regulators accept the benefit-risk profile, that could broaden the market beyond topical use alone rather than simply splitting the same treatment segment.

The road ahead

The safety discussion is likely to matter in review. Litfulo’s label carries a black box warning for higher risks of cancer and cardiovascular problems, which the report notes is a class-wide warning the FDA requires for JAK inhibitors, including Opzelura. That means the efficacy signal may need to be weighed against a known class constraint rather than a new safety surprise.

Pfizer is also moving into a busier field than it would have faced a few years ago. In July, AbbVie’s Rinvoq added non-segmental vitiligo to its label in Europe and is under FDA review in the indication. Teva said in July that it plans a Phase 2b vitiligo study for an IL-15-targeting antibody after Phase 1b results, and Argenx is pursuing the disease with a Forte Biosciences antibody that blocks IL-2 and IL-15 signaling.

For Pfizer, the immediate signal is less about first-mover advantage than about whether a company with an already approved JAK drug can use label expansion to claim a durable place in a market that is shifting from a single approved product toward a multi-mechanism category.